Women’s Health and Psychedelics – New Insights
Using validated behavior models and known standards, studies are finding significant differences between male and female rodents given psychedelic drugs.
Scientific Research
First Proof that Psilacetin is a Prodrug of Psilocin
Nichols and Frescas’ 1999 hypothesis becomes a validated scientific theory.
Study of Norpsilocin Derivatives Reveals the Potential Importance of Monoalkyl Tryptamines
Norpsilocin is not psychoactive but minor changes to its chemical structure translate into major changes in its pharmacology.
Magic Mushroom Formulations Update
Magic mushroom science marches on as understudied psilocybin derivatives start taking center stage.
Gut Feeling: Links Between LSD, Endocannabinoids, and the Microbiome
In the last 10 years, psychiatric interest in the use of psychedelics, such as psilocybin and LSD, has surged. A new study employed mice to examine how LSD could exert changes on the inflammatory response and the gut microbiome.
Abuse Potential: Considerations for Rescheduling MDMA and Psychedelics
Can the meteoric rise of psychedelics and entactogens clear the legal hurdles of abuse potential assessment and rescheduling?
Many Trips, Diminishing Returns: Cross-Tolerance Between LSD and DOI
Psychedelic drugs like LSD powerfully alter consciousness and promote neural plasticity, but drug tolerance occurs rapidly following the first dose. Although the mechanisms that underlie psychedelic tolerance may overlap with those that confer a therapeutic effect, until recently these mechanisms were unknown.
How To Stop A Psychedelic Trip: The Promise of Ketanserin
Psychedelic trips often unfold without issues, but what if a trip needs to be stopped? Drugs such as benzodiazepines and antipsychotics are recommended as rescue medications and have been around for decades. Can ketanserin be used as a more targeted trip stopper?
Psychedelic Brains In A Dish
Lab grown brains help to shed insight on 5-MeO-DMT mechanisms.
5-HT2A Virtual Chemical Screen Produces New Candidate Antidepressants
The serotonin receptor subtype 5-HT2A is key for the effects of many psychedelic substances in humans, but it is also a major drug target for new antidepressants. However, large challenges have prevented this therapeutic promise from being realised. Overcoming the early bottlenecks, innovative drug discovery methods have produced two new compounds with potential for therapeutic development.